Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines.
The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that both candidates could respectively bring real advantages to the treatment of chronic Hepatitis B and HIV, respectively.
The money raised until the 22nd of June will impulse the clinical development programs for both lead products. The company plans to carry out pivotal studies in Asia for ABX203 in the treatment of chronic Hepatitis B and Phase II clinical trial against HIV/AIDS.